Valley National Advisers’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $201K | Sell |
8,366
-1,445
| -15% | -$37.8K | 0.02% | 256 |
|
|
2026
Q1 | $275K | Sell |
9,811
-385
| -4% | -$10.3K | 0.04% | 223 |
|
|
2025
Q4 | $253K | Buy |
10,196
+265
| +3% | +$6.68K | 0.04% | 218 |
|
|
2025
Q3 | $253K | Buy |
9,931
+723
| +8% | +$17.8K | 0.04% | 209 |
|
|
2025
Q2 | $223K | Sell |
9,208
-1,835
| -17% | -$42.8K | 0.04% | 228 |
|
|
2025
Q1 | $279K | Buy |
11,043
+1,309
| +13% | +$34.3K | 0.05% | 204 |
|
|
2024
Q4 | $258K | Sell |
9,734
-8,214
| -46% | -$223K | 0.05% | 203 |
|
|
2024
Q3 | $519K | Sell |
17,948
-11,191
| -38% | -$326K | 0.09% | 162 |
|
|
2024
Q2 | $815K | Sell |
29,139
-3,800
| -12% | -$105K | 0.12% | 129 |
|
|
2024
Q1 | $914K | Buy |
32,939
+6,835
| +26% | +$190K | 0.14% | 125 |
|
|
2023
Q4 | $751K | Sell |
26,104
-5,647
| -18% | -$171K | 0.12% | 132 |
|
|
2023
Q3 | $1.05M | Buy |
31,751
+782
| +3% | +$27.7K | 0.18% | 101 |
|
|
2023
Q2 | $1.14M | Buy |
30,969
+224
| +0.7% | +$8.72K | 0.19% | 98 |
|
|
2023
Q1 | $1.23M | Sell |
30,745
-844
| -3% | -$36.5K | 0.22% | 91 |
|
|
2022
Q4 | $1.5M | Sell |
31,589
-579
| -2% | -$27.8K | 0.27% | 81 |
|
|
2022
Q3 | $1.42M | Sell |
32,168
-1,752
| -5% | -$85.1K | 0.3% | 73 |
|
|
2022
Q2 | $1.81M | Sell |
33,920
-374
| -1% | -$19.1K | 0.38% | 59 |
|
|
2022
Q1 | $1.78M | Sell |
34,294
-598
| -2% | -$31K | 0.34% | 68 |
|
|
2021
Q4 | $2.06M | Sell |
34,892
-38,095
| -52% | -$1.89M | 0.38% | 74 |
|
|
2021
Q3 | $3.14M | Sell |
72,987
-211
| -0.3% | -$9.35K | 0.57% | 33 |
|
|
2021
Q2 | $2.87M | Buy |
73,198
+56
| +0.1% | +$2.18K | 0.52% | 36 |
|
|
2021
Q1 | $2.65M | Buy |
73,142
+202
| +0.3% | +$7.17K | 0.52% | 33 |
|
|
2020
Q4 | $2.69M | Sell |
72,940
-3,470
| -5% | -$127K | 0.56% | 31 |
|
|
2020
Q3 | $2.66M | Buy |
76,410
+1,263
| +2% | +$44.3K | 0.61% | 27 |
|
|
2020
Q2 | $2.33M | Buy |
75,147
+247
| +0.3% | +$8.39K | 0.54% | 31 |
|
|
2020
Q1 | $2.32M | Sell |
74,900
-5,827
| -7% | -$199K | 0.64% | 31 |
|
|
2019
Q4 | $3M | Buy |
80,727
+1,030
| +1% | +$36.7K | 0.75% | 32 |
|
|
2019
Q3 | $2.72M | Sell |
79,697
-148
| -0.2% | -$5.38K | 0.75% | 35 |
|
|
2019
Q2 | $3.28M | Sell |
79,845
-876
| -1% | -$34.8K | 0.9% | 28 |
|
|
2019
Q1 | $3.25M | Sell |
80,721
-1,074
| -1% | -$43K | 0.93% | 23 |
|
|
2018
Q4 | $3.39M | Sell |
81,795
-2,298
| -3% | -$95.4K | 1.1% | 21 |
|
|
2018
Q3 | $3.52M | Buy |
84,093
+1,851
| +2% | +$71.3K | 1.22% | 24 |
|
|
2018
Q2 | $2.83M | Buy |
82,242
+2,170
| +3% | +$74.2K | 1.08% | 30 |
|
|
2018
Q1 | $2.7M | Buy |
80,072
+18,415
| +30% | +$633K | 1% | 26 |
|
|
2017
Q4 | $2.12M | Buy |
61,657
+29,322
| +91% | +$1,000K | 0.74% | 33 |
|
|
2017
Q3 | $1.09M | Sell |
32,335
-203
| -0.6% | -$6.52K | 0.37% | 50 |
|
|
2017
Q2 | $1.04M | Sell |
32,538
-2,001
| -6% | -$63.1K | 0.37% | 53 |
|
|
2017
Q1 | $1.12M | Sell |
34,539
-3,977
| -10% | -$125K | 0.43% | 47 |
|
|
2016
Q4 | $1.19M | Sell |
38,516
-768
| -2% | -$23.4K | 0.55% | 55 |
|
|
2016
Q3 | $1.26M | Buy |
39,284
+5,027
| +15% | +$168K | 0.65% | 48 |
|
|
2016
Q2 | $1.14M | Buy |
34,257
+9,058
| +36% | +$289K | 0.59% | 51 |
|
|
2016
Q1 | $709K | Buy |
25,199
+2,756
| +12% | +$78.7K | 0.38% | 72 |
|
|
2015
Q4 | $687K | Buy |
22,443
+6,239
| +39% | +$196K | 0.4% | 65 |
|
|
2015
Q3 | $483K | Sell |
16,204
-285
| -2% | -$9.14K | 0.29% | 91 |
|
|
2015
Q2 | $525K | Buy |
16,489
+6,724
| +69% | +$219K | 0.3% | 89 |
|
|
2015
Q1 | $322K | Buy |
9,765
+6,227
| +176% | +$198K | 0.19% | 110 |
|
|
2014
Q4 | $103K | Buy |
+3,538
| New | +$101K | 0.08% | 126 |
|
Other funds holding PFE
Valley National Advisers's PFE Position: Q2 2026 in Review
Valley National Advisers reduced its Pfizer (PFE) stake by 15% in Q2 2026, selling an estimated $37.8K and leaving 8,366 shares worth $201K. The position accounts for 0.02% of the portfolio, ranked #256.
Valley National Advisers first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $3.52M in Q3 2018. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Valley National Advisers held 8,366 shares of Pfizer worth $201K as of Q2 2026.
- Valley National Advisers sold 1,445 Pfizer shares in Q2 2026, an estimated $37.8K.
- Pfizer made up 0.02% of Valley National Advisers's portfolio in Q2 2026, its #256 holding.
- Valley National Advisers first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
- Valley National Advisers's Pfizer position peaked at $3.52M in Q3 2018.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.